| ELK1 |
Yes, downregulated in cancer |
[23] |
| SRF |
Yes, downregulated in cancer |
[23] |
| CREB |
To the best of our knowledge, there are no data available |
|
| IL-6 |
Promoter demethylation after ADC, LPS has no additional effect on demethylation, one position: nt-1099 is less methylated in PBMCs of patients with rheumatoid arthritis |
[29,30] |
| IL-8 |
7.0-fold increased expression after LPS with ADC-TSA (trichostatin A) treatment |
[24] |
| IL-6 |
2.5-fold increased expression after LPS with ADC-TSA (trichostatin A) treatment |
[24] |
| TNF-α |
1.6-fold increased expression after LPS with ADC-TSA (trichostatin A) treatment |
[24] |
| TLR-2 |
Hypomethylation is associated with increased proinflammatory response |
[25] |
| TLR-4 |
TLR-4 hypermethylation causes low response to LPS |
[26] |
| TLR-2, TLR-4, lipopolysaccharide-binding protein (LBP) and haptoglobin (HP) |
Promoters are opened after LPS, which may be caused by demethylation |
[27] |
